Search from website
Search from website
Figure 1. CE-SDS virtual gel output (LabChip GXII) for monoclonal antibody to sST2, clone 21E3 under non-reduced (NR, left) and reduced (R, right) conditions.
Figure 2. Analytical SEC of final product.
Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.
Figure 4. Octet BLI analysis, antibody was loaded on sensor for capture of sST2 protein in different concentrations.(for reference only; data shown are from a single production batch at release and may not be representative of other batches)
Catalogue #
R1-267-100
Name
Monoclonal antibody to sST2, clone 21E3, hIgG1
Target
Recombinant sST2 protein
Target Description
Recombinant human sST2 protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line.
Alternative Names
Soluble suppression of tumorigenicity-2, IL1RL1, interleukin-1 receptor-like 1, DER4, ST2, T1
Uniprot ID
Q01638
Clonality
Human monoclonal
Clone
21E3
Class
hIgG1
Reactivity
Binds to human sST2 protein.
Application
ELISA, CLIA
Protocol
Concentration
1 mg/ml
Buffer
PBS, pH 7.4
Related Products
sST2 antibody clone 21E3 has been identified as a recommended detection antibody with clone 21B6 (cat# R1-265-100) and clone 19G3 (cat# R1-266-100). The antibody pairs 19G3-21E3 and 2B6-21E3 were additionally validated in human serum.
Shipping
Shipping on dry ice.
Storage
Store in -65...-85 °C. Avoid multiple freeze-thaw cycles.
Background
The STS2 gene belongs to the interleukin-1 receptor host defence and inflammation family, also known as IL1RL-1. It encodes for two isoforms: transmembrane receptor form (ST2L) and truncated soluble receptor form (sST2), which the latter being detectable in human serum. Elevated serum levels of sST2 have been linked to a variety of medical conditions, including cardiovascular disease, asthma, and sepsis. sST2 has been shown to be a reliable biomarker for heart failure. The median concentration of sST2 in healthy individuals is 18 ng/mL. The levels are affected by age and sex. sST2 concentration greater than 35 ng/mL strongly indicates hospitalization and death in heart failure (HF) patients (Presage ST2 assay, Critical Diagnostics). sST2 may also be useful for predicting the risk of death or hospitalization in patients with myocardial infarction (MI). Studies have shown that sST2 serum levels peak one day after a cardiac incident
This product is for research use only
TECHNICAL ASSISTANCE
Please refer any technical questions to
technical.support@icosagen.com
© 2026 Icosagen
